1. BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Rationale for Targeting BTK in MCL

4. FDA-Approved BTK Inhibitors

5. Ibrutinib in R/R MCL

6. Other Ibrutinib-Associated Toxicities May Emerge With Longer-Term Use

7. Educating Patients About Ibrutinib-Associated Bleeding in Case of Surgery or Trauma

8. Extended Follow-Up of Ibrutinib in MCL: Pooled Analysis (N = 370)

9. Acalabrutinib in MCL

10. Using BTK Inhibitors in the Clinic: Expert Opinions

11. Oral Therapies Are Changing the Cancer Treatment Paradigm

12. In MCL, Progression on Ibrutinib Is Often Associated With Fulminant Progression

13. Ibrutinib Resistance in MCL Is Complex

14. Combination Approaches Under Study

15. Other Novel Approaches

16. Key Takeaways

17. Abbreviations